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Dear Editor,
Pyogenic liver abscess is an uncommon intra-abdominal in-
fection associated with high mortality. The liver is in contact
with massive quantities of blood from systemic and portal
circulation. Therefore, any breakdown of its immune system
can directly cause lethal infections. Patients with Klebsiella
pneumoniae primary liver abscess (KPPLA) have higher inci-
dences of diabetes or glucose intolerance compared to those
with other pyogenic liver abscess, but it is unknown how
diabetes influences the liver’s immunity including Kupffer’s
cells. Here, we present a case with primary myelofibrosis
(PMF) suffering from KPPLA during the course of
ruxolitinib, a JAK1 and JAK2 inhibitor.
A 78-year-old man had a diagnosis of JAK2V617F+ PMF.
Treatment with ruxolitinib 20 mg twice daily was initiated in
May 2015. At the 2-month follow-up, he was suffering from
herpes zoster and thrombocytopenia, so the dosage of
ruxolitinib was reduced to 10 mg twice daily. Since dosage
was reduced, absolute hemoglobin and thrombocyte counts
had been stable. In January 2016, he presented with fatigue,
fever with chills, and persistent right upper quadrant pain.
Blood pressure was 91/50 mmHg, pulse was 120 beats per
minute, respiratory rate was 26 breaths per minute, and oxy-
gen saturation was 98 % while he was breathing a room air. A
laboratory blood test showed elevated biliary and liver en-
zymes, prothrombin time (PT), activated partial thromboplas-
tin time, and fibrinogen degradation products (FDP), whereas
hemoglobin and platelets were decreased due to disseminated
intravascular coagulopathy (DIC), which was score 4 based
on DIC diagnostic criteria (systemic inflammatory response
syndrome, platelet count of 8.5 × 104/μL, FDP>10 μg/ml,
and PT-international normalized ratio > 1.2). The absolute
neutrophil count and immunoglobulin levels were normal.
Abdominal contrast-enhanced computer tomography scans
showed an abscess with a 5-cm radius (Fig. 1). Percutaneous
catheter drainage of abscess was performed, and piperacillin-
tazobactam 4.5 mg thrice daily was initiated. An alleviation of
fever was observed from the next day, and the volume of the
abscess dwindled considerably in 14 days. Klebsiella
pneumoniae was detected from the pus. Magnetic resonance
imaging did not reveal any predisposing intra-abdominal fac-
tors for abscess formation. The catheter was removed and the
patient was discharged from hospital continuing on cefcapene
100 mg trice daily for another 3 weeks.
Ruxolitinib interferes with a variety of immune cells and
their function [1–3]. In fact, the number and activity of im-
mune cells were diminishing in our case: B cells, 28/μl;
CD4+T cells, 50/μl; CD8+ T cells, 53/μl; and NK-cell activ-
ity, 4 % (normal 18–40). With severe impairment of the num-
ber and activity of NK cells, JAK mutations and STAT
Key Message JAK mutations and STAT deficiency can cause lack
circulating T and NK lymphocytes. We need to warrant not only viral
infection but also severe bacterial infections such as pyogenic liver
abscess that can be induced by immunosuppression by ruxolitinib, a
JAK1 and JAK2 inhibitor.
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deficiency can cause not only viral infection but also severe
bacterial infections [4]. The defect in cell-mediated immunity
combined with or without impaired function of B cells might
be induced by ruxolitinib, which is thought to be associated
with KPPLA.
ECOG, Eastern Cooperative Oncology Group; FDP, fibrin-
ogen degradation products; JAK, Janus kinase; KPPLA,
Klebsiella pneumoniae primary liver abscess; PMF, primary
myelofibrosis; PT, prothrombin time; STAT, signal transducer
and activator of transcription; DIC, disseminated intravascular
coagulopathy
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Fig. 1 a Liver abscess with a
5-cm radius before drainage. b
Diminished abscess after 14-day
catheter drainage
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